ASKA Pharmaceutical Co.,Ltd.

About ASKAAbout ASKA

Corporate Philosophy

Contribute toward the improvement of people's health and progress
in medicine through the development of innovative products

Top Message

  • President, Representative Director ASKA Pharmaceutical Co.,Lid.

Since its foundation, ASKA has developed business activities with the aim of becoming a trusted pharmaceutical company based on the business philosophy, “Contribute toward the improvement of people’s health and progress in the medicine through the development of innovative products”.

ASKA celebrated its 95th anniversary in June 2015. Toward its centenary in 2020, we will be a specialty pharma having a strong presence in the medical industry through creating unique pharmaceutical products.

Recently, the expectation for some medical services has been increasingly rising because of the wider range of medical needs. We mainly focus on three fields: Internal medicine, the obstetrics and gynecology department, and the urology department. We will apply the skills and experience over the company’s history with the development of innovative products for people’s health and quality of life in our specific fields.

Furthermore, ASKA promotes to “Construction of the Corporate Governance System” and “Thoroughness of Compliance”. We will promptly disclose to stakeholder to fulfill corporate social responsibility through indicating ethicality and transparency of management.

We aim to develop high-value medicines for the medical needs. ASKA will continue its unceasing efforts to become a corporation that obtains the trust from all stakeholders.

We will greatly appreciate your further guidance and encouragement.

Company Overview

(As of March 31, 2017)

Company Name

ASKA Pharmaceutical Co.,Ltd.


5-1, Shibaura 2-Chome, Minato-ku, Tokyo, 108-8532
Tel:+81-3-5484-8366 Fax: +81-3-5484-8302


June 16,1920


June 28,1929


Manufacturing,sale and import/export,etc.of pharmaceuticals,veterinary medicines,quasi-drugs,foods,and medical devices


Takashi Yamaguchi, President, Representative Director


¥1197.9 million

Shares issued




Number of employees


Main Bank

The Bank of Tokyo-Mitsubishi UFJ, Ltd.


Directors (Board Members)

Takashi Yamaguchi
President, Representative Director
Atsushi Maruo
Executive Director "Assistant to the President"
Kazuhiko Kato
Managing Director "Development" "Overseas Business" "Healthcare Business"
Yuichiro Fukui
Director, Executive Corporate Officer "Sales Management"
Sota Yamaguchi
Director, Executive Corporate Officer "Innovative Drug Discovery"
Ikuo Kumano
Director, Executive Corporate Officer "Production" "Head, Administrative Division"
Eiji Ueda
Director (Outside)
Yasunori Yoshimura
Director (Outside)
Michizo Yamanaka
Director (Outside)

Corporate Auditors(Board Members)

Morinobu Saito
Standing Corporate Auditor
Satoshi Komatsu
Standing Corporate Auditor
Eiichi Oriki
Corporate Auditor (Outside)
Takao Kimura
Corporate Auditor (Outside)

Corporate Officers

Makoto Murakami
Corporate Officer "Quality & Safety Assurance" "Project Manager, 100th Anniversary Project"
Koichi Hasumi
Corporate Officer "President, Representative Director, ASKA Pharma Medical Co., Ltd."
Hirokuni Teramoto
Corporate Officer "Audit" "Legal Affairs & Regulatory Compliance"
Takao Nakada
Corporate Officer "Head, Production Division"
Hidehisa Hamasaki
Corporate Officer "Head, Innovative Drug Discovery Division"
Kunihiro Gunji
Corporate Officer "Head, Development Division"
Yoshiki Niwayama
Corporate Officer "Unit Manager, Healthcare Business Unit"
Hideshige Kito
Corporate Officer "Head, Sales Division"


1920 Founder yasohachi Yamaguchi established
"Teikoku Hormone Research Institute"
1922 Thyroid hormone "THYRADIN" launched
1929 Reorganied as a corporation,
"Teikoku Hormone Mfg. Research Lavolratory Co., Ltd."
1936 Constructed Takatsu Factory(currently Kawasaki Research center)
in Kanagawa.
1945 Company name changed to "Teikoku Hormone Mfg. Co., Ltd."
1955 Shares listed on the Tokyo Stock Exchange.
1957 Veterinary medicine production and sales started.
1980 Iwaki Factory constructed in Fukushima
1981 Benign prostatic hyperplasia agent"Prostal Tablets 25" launched.
1986 H2-raceptor antagonists "Altat Capsule 75" launched
1991 Takashi Yamaguchi appointed as President.
1997 International Representative Office established in Frankfurt, Germany.
1999 Oral contraceptives "Ange 28" launched.
2001 Head Office building constructed in Shibaura, Minato-ku; office moved.
2005 Hyperlipidemic agent "LIPDIL" launched
2005 Teikoku Hormone and Grelan merged,
forming ASKA Pharmaceutical Co., Ltd.
2009 Menopause, postmenopausal syndrome agent
2011 Emergency contraceptives"NORLEVO" launched
2014 LH-RH derivative"LEUPRORELIN" launched
2014 Antihypertensive agents"CANDESARTAN" launched
2016 A poorly absorbable antimicrobial agent"RIFXIMA" launched


Head office

Head officeHead office

5-1, Shibaura 2-Chome, Minato-ku, Tokyo, 108-8532
Tel:+81-3-5484-8366 Fax: +81-3-5484-8302

Kawasaki institute

Kawasaki instituteKawasaki institute

36-1, Shimosakunobe 5-Chome, Kawasaki-shi, Takatsu-ku, Kanagawa, 213-8522
Tel:+81-44-833-5151 Fax: +81-44-833-9110

Iwaki factory

Iwaki factoryIwaki factory

1, Otsurugi, Izumimachishimogawa, Iwaki-shi, Fukushima, 971-8183
Tel:+81-246-56-2111 Fax: +81-246-56-2114